← Back to Blog
Medical Tourism

First-In-Class New Drugs in China: A Verification Checklist Before You Travel

OriEast Editorial Team•2026-11-18

Quick Answer

Use this page to quickly understand what kinds of topics we cover, who the content is most useful for, and where to go next.

Main topics
Medical Tourism
Best for
NMPA data shows 69 innovative drugs approved this year and 15 first-in-class medicines, several launched in China ahead of the US, EU and Japan. Here is how to verify real availability and self-pay prices before you travel.
Best next step
Read Patient Guides

Need help applying this to your own case?

OriEast can help turn what you learned here into the right next step for hospital choice, records preparation, or travel planning.

How OriEast helps

We help international patients move from reading and research to real medical coordination in China.

  • ✓Clarify whether this topic is relevant to your case or travel plan
  • ✓Shortlist the right hospital, service, or specialist pathway
  • ✓Review records and reduce planning mistakes before booking
  • ✓Support hospital coordination, travel timing, and next-step questions

Your records are only shared as needed to coordinate planning and specialist review.

A year-to-date statistic from China's drug regulator is quietly changing the maths for some international patients. According to National Medical Products Administration figures cited in recent reporting, 69 innovative drugs have been approved in China so far this year, 15 of them first-in-class medicines built on a new mechanism or a new target, and several have reached patients in China before reaching the United States, the European Union or Japan. For someone deciding whether to travel for care, that raises a sharper question than "is treatment cheap here." The real question is: can I actually get this specific new drug, at a quoted self-pay price, before my home country approves it? This guide turns that into a verifiable checklist for the patient groups it touches — oncology, nuclear medicine and imaging, and rare sleep disorders such as narcolepsy type 1.

Why a new drug can be usable in China before it is usable at home

The mechanism behind the "earlier here" pattern is not one trick but a few. Some files are submitted in parallel across major markets and China simply finishes first. The reporting above describes a new-mechanism oral tablet for narcolepsy type 1 that was filed simultaneously in China, the United States, Japan and the European Union, and was approved first by China's regulator. It also describes a first-in-class factor XI inhibitor whose domestic review was reportedly completed within about six months, while the US and EU pathways were still ongoing. A separate industry analysis notes that China now launches more than 400 international multi-centre clinical trials a year, which is part of why data for some programmes matures here on a competitive timeline.

The important caution runs the other way. A commercial deal is not an approval. That same industry reporting puts 2025 outbound-licensing activity for Chinese innovative drugs above 150 deals, with upfront payments still around five percent of total deal value — meaning most of the money is contingent on global clinical and manufacturing work that is not finished. So when you read that a pharmaceutical company in your own country has licensed a Chinese-developed drug, that is a business milestone, not a guarantee that the medicine will reach your local pharmacy soon. The gap between "licensed" and "on the shelf" is exactly where a travel-for-access conversation can go wrong if you do not verify.

The medicines reported to have launched first in China, by indication

The table below groups the specific products named in the NMPA-citing report into a status-and-timeline comparison. Treat each row as a starting point for verification, not as a price or a promise of stocking — those are decided hospital by hospital.

Medicine (as reported)Patient groupReported China statusReported status abroadWhat to confirm before you travel
New-mechanism oral tablet for narcolepsy type 1 (奥普雷顿片)Rare sleep disorder, narcolepsy type 1Approved in China first among the synchronised filingsParallel filings in US, Japan, EUExact INN, brand, dose and per-pack self-pay price
First-in-class factor XI inhibitor tablet (阿舒克森片)Anticoagulation / clot-risk patientsReported launched after roughly six-month domestic reviewUS, EU still on filing pathwayApproved indication, your eligibility, monthly cost
Technetium-99m [99mTc] labelled peptide injection (锝[99mTc]佩昔瑞特加肽注射液)Oncology / nuclear-medicine imagingDescribed in the report as a world-first radioactive innovative drugCompare against local imaging agentsWhether the scan is offered to self-pay outpatients and at what price

For oncology and nuclear-medicine patients, the radiopharmaceutical line matters most. A diagnostic imaging injection changes what a workup can detect, but it is delivered inside a hospital's nuclear-medicine department on a scheduled slot, so its "availability" is really about whether that department accepts an international self-pay patient and what it charges — a question for the institution, not for a regulator's approval list. For rare sleep-disorder patients, the narcolepsy type 1 tablet is the clearest example of a synchronized global filing where China approved first; here the practical step is confirming the licensed brand presentation and a sustainable self-pay supply, since you will likely continue treatment at home.

Your verification checklist: availability and self-pay price

The whole point of a "China-first" story is that it only helps you if the drug is genuinely prescribable to you, at a known price, before you buy a plane ticket. Use the generic name plus the brand name — that is the single reliable method.

  1. Pin down both names. Take the international nonproprietary name (the INN / generic) and the Chinese generic name exactly as it appears on the approval, such as the characters shown in the table above. A hospital's international medical department can search its own formulary by either; a vague description cannot be checked.
  2. Ask three fixed questions in writing. Is this specific product stocked now? Can a self-pay international patient be prescribed it, subject to a physician's assessment? What is the per-dose or monthly price, exclusive of consultation and tests?
  3. Treat every figure as a quote, not a price. Drug costs, imaging fees and ward charges vary by city, by institution and by tier. Any number you receive should be confirmed as the hospital's own final quote before it enters your budget — do not assume a figure you read online.
  4. Confirm the prescribing pathway, not just the shelf. For several of these medicines a foreign patient still needs an in-person review, eligibility screening and a specialist sign-off; the prescription decision is not automatic even when the drug is in stock.
  5. Check who will follow up. If you go home mid-course, ask how prescriptions, monitoring and adverse-event support are handled after you leave.

OriEast runs this kind of formulary and pricing query on your behalf before you commit to travel, books the appointment through the hospital's international channel (see our appointment service), and can match you to an institution through our hospital directory.

If you are travelling specifically for cancer care

New systemic drugs rarely arrive alone — they intersect with established programmes. Patients weighing immunotherapy, targeted therapy or cellular treatment should evaluate these first-in-class options alongside China's existing oncology pathways rather than as a substitute for them; our pages on cancer treatment in China and CAR-T therapy in China explain how those services are organised and quoted. For imaging-driven decisions, a newer radiopharmaceutical may reshape staging, which is worth raising directly with the treating team. The broader planning context, from records to logistics, is covered in our complete medical tourism guide.

A necessary boundary, stated plainly: nothing here is a treatment recommendation. Whether any of these medicines is right for you, and whether combining them with your current therapy is safe, is a clinical decision. Any specific treatment plan must be assessed in person by a licensed physician.

A realistic timeline before you fly

A defensible plan inverts the usual mistake of booking travel first. Start with documentation — translated records, imaging, pathology and your current medication list — then run the availability-and-price checklist above and get a confirmed appointment slot in writing. Only after a self-pay price and a prescribing pathway are agreed should you lock dates; build the medical visa route around a confirmed schedule, and leave buffer days in case the treating physician wants additional tests before prescribing. The travel story is the easy half; the formulary confirmation is the part that decides whether the trip is worth it.

Before you book anything

If you are evaluating whether a first-in-class medicine that is approved in China before your home market is realistically accessible to you, the next step is to have your case checked against current hospital availability rather than against an approval headline. Send us your diagnosis and the specific drug you have in mind through our case evaluation, and OriEast will help verify stocking and self-pay pricing, arrange the appointment, and provide translation and care coordination through your visit. For questions about a particular product or institution, contact our team before you commit to travel.

Next step

If this topic is relevant to your treatment or travel plan, these pages are the best next place to continue.